A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2019
At a glance
- Drugs HPN 424 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Harpoon Therapeutics
- 02 Jan 2019 According to a Harpoon Therapeutics media release, the company expects to report additional data from this ongoing trial in 2019.
- 02 Jan 2019 Results(n=7) presented in a Harpoon Therapeutics media release.
- 30 Jul 2018 Status changed from not yet recruiting to recruiting.